Buprenorphine has potent kappa opioid receptor antagonist activity.
about
HS-599: a novel long acting opioid analgesic does not induce place-preference in ratsThe effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesEffects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in miceEvaluation of opioid modulation in major depressive disorderBuprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawalBuprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor systemOpioid partial agonist buprenorphine dampens responses to psychosocial stress in humansOligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancyBuprenorphine differentially alters opioid receptor adaptation in rat brain regions.Role of buprenorphine in the management of heroin addiction.Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.Mu opioids and their receptors: evolution of a concept.The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.Buprenorphine-naloxone therapy in pain management.Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.Perioperative Pain Management for Patients on Chronic Buprenorphine: A Case Report.Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.Buprenorphine in the treatment of opiate dependence.Going beyond efficacy: strategies for cancer pain management.Cardiorespiratory effects of four opioid-tranquilizer combinations in dogs.Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.Induction of patients with moderately severe methadone dependence onto buprenorphine.Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence.Buprenorphine-cocaine interactions in mice: effect on locomotor activity and hole-dipping behaviour.Buprenorphine and pain treatment in pediatric patients: an update.The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review
P2860
Q24673536-3F0C6473-140D-4D6E-AB1F-FA794F9D2EF9Q30490602-D9E61065-7501-4A1E-8772-62A04FA3D211Q34272502-AA9724E5-BFF8-4759-AE20-645A7F457824Q34436340-9BD21C51-D856-4D3F-9277-3A43DDE8B4C7Q34454397-CCBA145D-ECEF-4E06-BC09-303F5C44A4D7Q34552092-021F3AE9-262D-4C0D-8C23-2DE31A8881C0Q34561447-E12D5CF5-4ED5-4081-8544-2167565F5816Q34979634-17D5E9AC-5862-440E-86EE-C94A8DBA661AQ35552420-0CF9B9A9-AF04-42B6-A7A7-1D2AD8DFB8EAQ35653140-4A8994E4-FC24-48DD-9E55-E7E2A123E016Q36376715-57929886-FF8D-476B-945D-BDF1A68E9E36Q36838054-F48D0D6C-9C71-40FF-83A0-5FA1A4E9C8A4Q37236111-7C835321-E009-430C-9390-EDB73D329716Q37267983-20285BB9-09D5-4890-ABDD-6C209905E503Q37722356-B149A65A-3ED8-40E0-82AB-5AB81DF3395BQ39334344-5333B444-13D9-4993-8DE3-084DE8F9772EQ39361359-5A3F641C-7A75-42D3-935D-7C30CCCDB839Q41657869-48617B17-DF44-4553-8425-9DBF5B40F604Q42005602-3FE5D3F1-4B39-4808-9216-0C54029479A7Q42566902-532B77A0-1676-4902-AC42-D752FC61105CQ42596062-104EF4C5-4D2F-48A5-A505-1558C7180B34Q42962930-23FF50A5-701E-42DB-9E65-D07A08926656Q42976344-F5873F85-C201-4C2F-8F79-5E1EB24B9A0FQ44337909-365376B7-877A-4BB1-8E5D-AB6B3D98956EQ44352016-5836E1E4-6006-47BF-AEF1-C201CFFDF15AQ46726322-778B9060-831E-4A15-972E-D676B95B9741Q46970878-B16D8F22-414D-4368-A5FE-C30BAA1EDAD1Q51662333-FFCE5F65-C51E-4502-8007-4BFCFC2B3EC1Q55078240-816ABE5E-6B3C-4999-A08A-3CDDD4AE8FBCQ58776450-F95AB945-39B5-46FE-8002-A0281C97B307
P2860
Buprenorphine has potent kappa opioid receptor antagonist activity.
description
1987 nî lūn-bûn
@nan
1987 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Buprenorphine has potent kappa opioid receptor antagonist activity.
@ast
Buprenorphine has potent kappa opioid receptor antagonist activity.
@en
Buprenorphine has potent kappa opioid receptor antagonist activity.
@nl
type
label
Buprenorphine has potent kappa opioid receptor antagonist activity.
@ast
Buprenorphine has potent kappa opioid receptor antagonist activity.
@en
Buprenorphine has potent kappa opioid receptor antagonist activity.
@nl
prefLabel
Buprenorphine has potent kappa opioid receptor antagonist activity.
@ast
Buprenorphine has potent kappa opioid receptor antagonist activity.
@en
Buprenorphine has potent kappa opioid receptor antagonist activity.
@nl
P1433
P1476
Buprenorphine has potent kappa opioid receptor antagonist activity.
@en
P2093
Leander JD
P304
P356
10.1016/0028-3908(87)90112-2
P577
1987-09-01T00:00:00Z